The vaccine against coronavirus Russian Sputnik V has shown an efficacy of 97.6% during the vaccination campaign that has already covered 3.8 million Russians, the Russian Direct Investment Fund (FIDR) reported today.
“Analysis of data on the infection rate of almost 4 million vaccinated people in Russia shows that the efficacy of the vaccine is even higher (than the 91.6% efficacy, announced by The Lancet magazine), reaching the 97.6% “Kiril Dmitriev, director of the FIDR, said in a statement.
These data confirm that the Russian drug offers, according to Dmitriev, “One of the best rates of protection against coronavirus among all vaccines.”
FIDR bases its estimate on the results obtained by the registry of vaccinated persons of the Russian Ministry of Health and that of patients from covid-19 detected by the Unified State Health Information System.
According to the fund, the contagion rate of 3.8 million Russians vaccinated with both components of the drug between December 5, 2020 and March 31, 2021 was only 0.027%.
As the vaccine requires time to generate immunity in the human organism, people who became ill after 35 days of receiving the first dose were counted.
In contrast, the infection rate among the unvaccinated adult population was 1.1% during the same period.
Alexander Gintsburg, director of the Gamaleya Center, went further by stating that “the actual efficacy of the vaccine Sputnik V it may be even higher than the results show “ of the analysis, since the investigation does not contemplate the lapse of time between the actual contagion and the diagnosis of the disease.
FIDR announced that the results of this study will be published in a specialized medical journal next May, without specifying which one.
Until now, the Sputnik V It has been recorded in 60 countries with a total population of 3 billion people.
Russia, which has three self-made anticovid vaccines, plans to produce 88 million coronavirus vaccines in the first half of 2021, of which 83 million would correspond to Sputnik V.